Abstract
Src kinase plays a key role in multiple signalling pathways regulating diverse cell functions from proliferation and survival to invasion and angiogenesis. In breast cancer, both Src protein levels and kinase activity are frequently elevated and its important role in these oncogenic processes make it a potential target for therapeutic intervention. Importantly, recent evidence has revealed a role for Src in mediating anti-hormone action and in acquired endocrine resistance. A number of small molecule inhibitors of Src kinase have been developed with preclinical data demonstrating their effectiveness at suppressing breast cancer growth and invasion in vitro whilst inhibiting disease spread in vivo. Significantly, there appears to be added benefit when these agents are given in combination with anti-oestrogens. These new findings suggest that Src inhibitors might have therapeutic value in breast cancer patients.
Keywords: Breast cancer, endocrine resistance, Src inhibitor, Src kinase
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Src as a Therapeutic Target in Breast Cancer
Volume: 8 Issue: 4
Author(s): Liam Morgan, Robert I. Nicholson and Stephen Hiscox
Affiliation:
Keywords: Breast cancer, endocrine resistance, Src inhibitor, Src kinase
Abstract: Src kinase plays a key role in multiple signalling pathways regulating diverse cell functions from proliferation and survival to invasion and angiogenesis. In breast cancer, both Src protein levels and kinase activity are frequently elevated and its important role in these oncogenic processes make it a potential target for therapeutic intervention. Importantly, recent evidence has revealed a role for Src in mediating anti-hormone action and in acquired endocrine resistance. A number of small molecule inhibitors of Src kinase have been developed with preclinical data demonstrating their effectiveness at suppressing breast cancer growth and invasion in vitro whilst inhibiting disease spread in vivo. Significantly, there appears to be added benefit when these agents are given in combination with anti-oestrogens. These new findings suggest that Src inhibitors might have therapeutic value in breast cancer patients.
Export Options
About this article
Cite this article as:
Morgan Liam, Nicholson I. Robert and Hiscox Stephen, Src as a Therapeutic Target in Breast Cancer, Endocrine, Metabolic & Immune Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187153008786848295
DOI https://dx.doi.org/10.2174/187153008786848295 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Treatments for Iron Deficiency (ID): Prospective Organic Iron Fortification
Current Pharmaceutical Design Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Pluripotent Stem Cell-Derived Somatic Stem Cells as Tool to Study the Role of MicroRNAs in Early Human Neural Development
Current Molecular Medicine The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells
Current Drug Delivery Adenosine and Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Genetic Polymorphisms of Drug Metabolizing Enzymes and Transporters: The Long Way from Bench to Bedside
Current Topics in Medicinal Chemistry Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Anticancer Activity of 5-Benzylidene-2-Phenylimino-1, 3-Thiazolidin-4-one (BPT) Analogs
Medicinal Chemistry Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials
Current Medicinal Chemistry Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Continuous Hypoxia and Glucose Metabolism: The Effects on Gene Expression in Mcf7 Breast Cancer Cell Line
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism Different Targeting Strategies for Treating Breast Cancer Bone Metastases
Current Pharmaceutical Design Pharmacological and Cellular Significance of Triazole-Surrogated Compounds
Current Organic Chemistry Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry